产品名称	Sirukumab (anti-IL-6), 白细胞介素 6 抑制剂
别名	西鲁库单抗 \| 西卢卡单抗(抗 IL-6)
英文别名	Interleukin BSF 2 antibody \| B cell differentiation factor antibody \| B cell stimulatory factor 2 antibody \| B-cell stimulatory factor 2 antibody \| BSF 2 antibody \| BSF-2 antibody \| BSF2 antibody \| CDF antibody \| CTL differentiation factor antibody \| Cyto
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	IL6
种属反应性	人(Human)
偶联	Unconjugated
作用类型	抑制剂
作用机制	白细胞介素 6 抑制剂

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	144.58 kDa
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1194585-53-9
分子类型	抗体

图片

ELISA: Sirukumab (anti-IL-6) (Ab175656)

Sirukumab (anti-IL-6) (Ab175656) - ELISA
Immobilized hu-IL-6 at 1.0 μg/mL can bind Sirukumab (anti-IL-6) (Ab175656) with the EC₅₀ of 45.55 ng/mL.

SEC: Sirukumab (anti-IL-6) (Ab175656)

Sirukumab (anti-IL-6) (Ab175656) - SEC
The purity of Sirukumab (anti-IL-6) (Ab175656) is more than 95% verified by HPLC.

关联靶点（人）

IL6 Tclin 白细胞介素-6(Interleukin-6) (0 活性数据)

点击查看靶蛋白信息： IL6

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

技术规格说明书

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到5个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F1013239	分析证书	24-11-01	Ab175656
ZJ24F1013238	分析证书	24-11-01	Ab175656
ZJ24F1013237	分析证书	24-11-01	Ab175656
ZJ23F1202212	分析证书	23-12-28	Ab175656
ZJ23F1202211	分析证书	23-12-28	Ab175656

可替换产品

参考文献

1. Nishimoto N. (2006) Interleukin-6 in rheumatoid arthritis.. Curr Opin Rheumatol, 18 (3): (277-81). [PMID:16582692] [10.1021/op500134e]
2. Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM, Zhou H. (2011) Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.. Br J Clin Pharmacol, 72 (2): (270-81). [PMID:21392075] [10.1021/op500134e]
3. Hepgul N, Cattaneo A, Agarwal K, Baraldi S, Borsini A, Bufalino C, Forton DM, Mondelli V, Nikkheslat N, Lopizzo N et al.. (2016) Transcriptomics in Interferon-α-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression.. Neuropsychopharmacology, 41 (10): (2502-11). [PMID:27067128] [10.1021/op500134e]
4. Rovin BH, van Vollenhoven RF, Aranow C, Wagner C, Gordon R, Zhuang Y, Belkowski S, Hsu B. (2016) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.. Arthritis Rheumatol, 68 (9): (2174-83). [PMID:27110697] [10.1021/op500134e]
5. Du Preez A, Leveson J, Zunszain PA, Pariante CM. (2016) Inflammatory insults and mental health consequences: does timing matter when it comes to depression?. Psychol Med, 46 (10): (2041-57). [PMID:27181594] [10.1021/op500134e]
6. Young JJ, Bruno D, Pomara N. (2014) A review of the relationship between proinflammatory cytokines and major depressive disorder.. J Affect Disord, 169 (13): (15-20). [PMID:25128861] [10.1021/op500134e]
7. Money KM, Olah Z, Korade Z, Garbett KA, Shelton RC, Mirnics K. (2016) An altered peripheral IL6 response in major depressive disorder.. Neurobiol Dis, 89 (13): (46-54). [PMID:26804030] [10.1021/op500134e]
8. Zhang C, Wu Z, Zhao G, Wang F, Fang Y. (2016) Identification of IL6 as a susceptibility gene for major depressive disorder.. Sci Rep, 6 (13): (31264). [PMID:27502736] [10.1021/op500134e]
9. Sun Y, Wang D, Salvadore G, Hsu B, Curran M, Casper C, Vermeulen J, Kent JM, Singh J, Drevets WC et al.. (2017) The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.. Brain Behav Immun, 66 (13): (156-164). [PMID:28676350] [10.1021/op500134e]
10. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.. Science, 300 (5628): (2101-4). [PMID:12829785] [10.1021/op500134e]
11. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al.. (2014) Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.. MAbs, 6 (3): (774-82). [PMID:24670876] [10.1021/op500134e]
12. Kang S, Tanaka T, Narazaki M, Kishimoto T. (2019) Targeting Interleukin-6 Signaling in Clinic.. Immunity, 50 (4): (1007-1023). [PMID:30995492] [10.1016/j.immuni.2019.03.026]
13. Q Y Chen. (1992-09-01) [Stable and efficient expression of human interleukin-6 cDNA in mammalian cells after gene transfer].. Zhonghua zhong liu za zhi [Chinese journal of oncology], 14 ((5)): (340-344). [PMID:1291290]
14. H C van Zaanen,R P Koopmans,L A Aarden,H J Rensink,J M Stouthard,S O Warnaar,H M Lokhorst,M H van Oers. (1996-09-15) Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.. The Journal of clinical investigation, 98 ((6)): (1441-1448). [PMID:8823310]
15. Kim D, Won HY, Hwang ES, Kim YK, Choo HP.. (2017) Synthesis of benzoxazole derivatives as interleukin-6 antagonists.. Bioorg Med Chem, 25 (12): (3127-3134). [PMID:28442260] [10.1016/j.bmc.2017.03.072]
16. May, L T LT, Shaw, J E JE, Khanna, A K AK, Zabriskie, J B JB and Sehgal, P B PB.. (1991) Marked cell-type-specific differences in glycosylation of human interleukin-6.. Cytokine, [PMID:1883960]
17. Lütticken, C C, Krüttgen, A A, Möller, C C, Heinrich, P C PC and Rose-John, S S.. (1991) Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6.. FEBS letters, (6): [PMID:2037043]
18. Clogston, C L CL, Boone, T C TC, Crandall, B C BC, Mendiaz, E A EA and Lu, H S HS.. (1989) Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor.. Archives of biochemistry and biophysics, [PMID:2472117]
19. Ming, J E JE, Cernetti, C C, Steinman, R M RM and Granelli-Piperno, A A.. (1989) Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium.. The Journal of molecular and cellular immunology : JMCI, [PMID:2610854]
20. Tonouchi, N N, Miwa, K K, Karasuyama, H H and Matsui, H H.. (1989) Deletion of 3' untranslated region of human BSF-2 mRNA causes stabilization of the mRNA and high-level expression in mouse NIH3T3 cells.. Biochemical and biophysical research communications, (15): [PMID:2789513]
21. Zilberstein, A A, Ruggieri, R R, Korn, J H JH and Revel, M M.. (1986) Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines.. The EMBO journal, [PMID:3023045]
22. Wong, G G GG, Witek-Giannotti, J J, Hewick, R M RM, Clark, S C SC and Ogawa, M M.. (1988) Interleukin 6: identification as a hematopoietic colony-stimulating factor.. Behring Institute Mitteilungen, [PMID:3266463]
23. Van Damme, J J and 5 more authors.. (1988) Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:3279116]
24. Brakenhoff, J P JP, de Groot, E R ER, Evers, R F RF, Pannekoek, H H and Aarden, L A LA.. (1987) Molecular cloning and expression of hybridoma growth factor in Escherichia coli.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:3320204]
25. Hirano, T T and 9 more authors.. (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.. Nature, [PMID:3491322]
26. Yasukawa, K K and 6 more authors.. (1987) Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene.. The EMBO journal, [PMID:3500852]
27. May, L T LT, Helfgott, D C DC and Sehgal, P B PB.. (1986) Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:3538015]
28. Haegeman, G G and 5 more authors.. (1986) Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts.. European journal of biochemistry, (15): [PMID:3758081]
29. Breton, J J and 8 more authors.. (1995) Structure, stability and biological properties of a N-terminally truncated form of recombinant human interleukin-6 containing a single disulfide bond.. European journal of biochemistry, (15): [PMID:7851440]
30. Nishimura, C C, Watanabe, A A, Gouda, H H, Shimada, I I and Arata, Y Y.. (1996) Folding topologies of human interleukin-6 and its mutants as studied by NMR spectroscopy.. Biochemistry, (9): [PMID:8555185]
31. Somers, W W, Stahl, M M and Seehra, J S JS.. (1997) 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling.. The EMBO journal, (3): [PMID:9118960]
32. Xu, G Y GY and 6 more authors.. (1997) Solution structure of recombinant human interleukin-6.. Journal of molecular biology, (2): [PMID:9159484]
33. Fishman, D D and 6 more authors.. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.. The Journal of clinical investigation, (1): [PMID:9769329]
34. Foster, C B CB and 11 more authors.. (2000) An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus.. Blood, (1): [PMID:11001912]
35. Ota, N N and 8 more authors.. (2001) A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density.. Journal of human genetics, [PMID:11355017]
36. Chung, Hye Won HW and 8 more authors.. (2003) Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women.. Journal of human genetics, [PMID:12768442]
37. Nemeth, Elizabeta E and 6 more authors.. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.. The Journal of clinical investigation, [PMID:15124018]
38. Wolsk, Emil E, Mygind, Helene H, Grøndahl, Thomas S TS, Pedersen, Bente K BK and van Hall, Gerrit G.. (2010) IL-6 selectively stimulates fat metabolism in human skeletal muscle.. American journal of physiology. Endocrinology and metabolism, [PMID:20823453]
39. Ellingsgaard, Helga H and 20 more authors.. (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.. Nature medicine, (30): [PMID:22037645]
40. Taniguchi, Koji K and 17 more authors.. (2015) A gp130-Src-YAP module links inflammation to epithelial regeneration.. Nature, (5): [PMID:25731159]
41. Tagliabracci, Vincent S VS and 14 more authors.. (2015) A Single Kinase Generates the Majority of the Secreted Phosphoproteome.. Cell, (18): [PMID:26091039]
42. Larsen, Jakob Vejby JV and Petersen, Claus Munck CM.. (2017) SorLA in Interleukin-6 Signaling and Turnover.. Molecular and cellular biology, (1): [PMID:28265003]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Sirukumab (anti-IL-6), 白细胞介素 6 抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器